C12N 9/644
Coagulation factor ixa
Official title: {Coagulation factor IXa (3.4.21.22)}
C12N9/644 (Coagulation factor ixa) appears on 397 US grants and 579 published applications in this corpus.
Search patents in C12N- Granted patents
- 397
- Published applications
- 579
- Assignees
- 213
- Inventors
- 652
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 3 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 7 | 0 |
| 1999 | 10 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 1 |
| 2002 | 4 | 8 |
| 2003 | 7 | 7 |
| 2004 | 4 | 14 |
| 2005 | 2 | 10 |
| 2006 | 3 | 8 |
| 2007 | 6 | 8 |
| 2008 | 9 | 17 |
| 2009 | 4 | 9 |
| 2010 | 7 | 21 |
| 2011 | 10 | 19 |
| 2012 | 6 | 23 |
| 2013 | 6 | 27 |
| 2014 | 17 | 54 |
| 2015 | 20 | 32 |
| 2016 | 25 | 45 |
| 2017 | 32 | 28 |
| 2018 | 17 | 31 |
| 2019 | 25 | 35 |
| 2020 | 26 | 34 |
| 2021 | 27 | 50 |
| 2022 | 14 | 26 |
| 2023 | 17 | 20 |
| 2024 | 11 | 17 |
| 2025 | 19 | 22 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inter-application workflow performance analytics18 Aug 2026US 12,711,443 B2Box, Inc.
- Hemophilia B rat model2 Jun 2026US 12,642,256 B2Toolgen Incorporated
- Factor IX variants and uses thereof in therapy17 Mar 2026US 12,577,552 B2CSL Innovation Pty Ltd
- Methods and means for the prevention and/or treatment of hemophilic arthropathy in hemophilia10 Feb 2026US 12,544,459 B2uniQure biopharma B.V.
- Delivery and formulation of engineered nucleic acids23 Dec 2025US 12,502,431 B2ModernaTX, Inc.
- Engineered cell preparations for treatment of hemophilia24 Sep 2026US 2026/0286298 A1Be Biopharma, Inc.
- Nucleic acid constructs and methods of use17 Sep 2026US 2026/0273105 A1Intellia Therapeutics, Inc.
- Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof3 Sep 2026US 2026/0258443 A1Kanglin Biotech (Hangzhou) Co., Ltd.
- Use of lentiviral vectors expressing factor ix23 Jul 2026US 2026/0209799 A1Bioverativ Therapeutics Inc.
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
Most cited
By later US patents
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008